Enanta Pharmaceuticals (NASDAQ:ENTA) Lifted to “Sell” at BidaskClub

BidaskClub upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a strong sell rating to a sell rating in a research note published on Friday, BidAskClub reports.

A number of other equities analysts have also commented on the stock. JMP Securities lowered shares of Enanta Pharmaceuticals from an outperform rating to a market perform rating in a report on Friday, November 22nd. JPMorgan Chase & Co. downgraded Enanta Pharmaceuticals from a neutral rating to an underweight rating and decreased their price objective for the company from $86.00 to $57.00 in a report on Thursday, September 26th. Berenberg Bank set a $130.00 target price on Enanta Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, September 18th. Zacks Investment Research lowered Enanta Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, November 22nd. Finally, ValuEngine raised Enanta Pharmaceuticals from a buy rating to a strong-buy rating in a report on Friday, November 1st. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $96.50.

NASDAQ:ENTA traded up $1.10 during mid-day trading on Friday, hitting $64.08. 143,448 shares of the company’s stock were exchanged, compared to its average volume of 211,996. The company has a 50 day simple moving average of $61.83 and a 200-day simple moving average of $73.38. Enanta Pharmaceuticals has a fifty-two week low of $57.15 and a fifty-two week high of $106.80. The firm has a market capitalization of $1.26 billion, a P/E ratio of 29.00 and a beta of 0.90.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Thursday, November 21st. The biotechnology company reported $0.44 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.56 by ($0.12). Enanta Pharmaceuticals had a return on equity of 10.46% and a net margin of 22.60%. The business had revenue of $51.30 million for the quarter, compared to the consensus estimate of $55.95 million. During the same period in the previous year, the firm earned $1.30 earnings per share. The company’s revenue was down 23.7% compared to the same quarter last year. On average, analysts forecast that Enanta Pharmaceuticals will post -0.77 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. acquired a new position in shares of Enanta Pharmaceuticals in the 2nd quarter worth approximately $34,000. Robeco Institutional Asset Management B.V. acquired a new position in shares of Enanta Pharmaceuticals in the 3rd quarter valued at about $48,000. Bank of Montreal Can lifted its stake in shares of Enanta Pharmaceuticals by 198.3% in the 2nd quarter. Bank of Montreal Can now owns 2,300 shares of the biotechnology company’s stock valued at $194,000 after purchasing an additional 1,529 shares during the period. Jane Street Group LLC acquired a new position in shares of Enanta Pharmaceuticals in the 2nd quarter valued at about $208,000. Finally, GAM Holding AG bought a new stake in shares of Enanta Pharmaceuticals during the 2nd quarter valued at about $215,000. 89.79% of the stock is owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

See Also: Net Margin – Understanding the Different Kinds of Profit

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.